A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma

Investigational New Drugs

Volumn 32, Issue 4, 2014, Pages 723-728

  Ooka, Yoshihiko ^a   Chiba, Tetsuhiro ^a   Ogasawara, Sadahisa ^a   Arai, Kuniaki ^b   Suzuki, Eiichiro ^a   Tawada, Akinobu ^a   Yamashita, Tatsuya ^b   Kanai, Fumihiko ^a   Kaneko, Shuichi ^b   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Hepatocellular carcinoma; Liver cancer; Molecular targeted agent; S 1; Sorafenib

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CARBANILAMIDE DERIVATIVE; DRUG COMBINATION; NICOTINAMIDE; OTERACIL; S 1 (COMBINATION); SORAFENIB; TEGAFUR;

AGED; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; DRUG COMBINATION; FEMALE; HUMAN; LIVER NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; DRUG COMBINATIONS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NIACINAMIDE; OXONIC ACID; PHENYLUREA COMPOUNDS; PROSPECTIVE STUDIES; TEGAFUR;

EID: 84904551604     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0077-6     Document Type: Article

References (13)

1. Ferlay J, Shin HR, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer 127:2893-2917
2. Wilhelm SM, Carter C, Tang L et al (2004) Bay 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109 (Pubitemid 39331023)
3. Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34
4. Llovet JM, Ricci S, Mazzaferro Vet al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
5. Takimoto CH, Awada A (2008) Safety and anti-tumor activity of sorafenib (nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol 61:535-548
6. Shirasaka T, Shimamato Y, Ohshimo H et al (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548-557 (Pubitemid 26276346)
7. Shirasaka T (2009) Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol 39:2-15
8. Saif MW, Syrigos KN, Katirtzoglou NA (2009) S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs 18:335-348
9. Furuse J, Okusaka T, Kaneko S et al (2010) Phase I/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced hepatocellular carcinoma. Cancer Sci 101:2606-2611
10. Zhai JM, Yin XY, Lai YR (2013) Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1. Cancer Chemother Pharmacol 71:1255-1264
11. Ogasawara S, Kanai F, Obi S et al (2011) Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma. Hepatol Int 5:850-856
12. Lee SJ, Lee J, Park SH et al (2012) Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. Investig New Drugs 30:1540-1547
13. Furuse J, Ishii H, Nakachi K et al (2008) Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 99:159-165 (Pubitemid 350239045)